PMID-29872467 – Octreotide Review Use in Treating NETs
Broder MS, Beenhouwer D, Guenther JR, Neary MP, Cherepanov D. Octreotide – A Review of its Use in Treating Neuroendocrine Tumours. Eur Endocrinol. 2018;14(2):87-92.
Quick Reference
| Property | Value |
|---|---|
| PMID | 29872467 |
| DOI | 10.17925/EE.2018.14.2.87 |
| Year | 2018 |
| Journal | European Endocrinology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review article) |
| Peptide(s) Studied | Octreotide |
Key Findings
- Comprehensive review summarizing three decades of octreotide use in NETs since FDA approval in 1988
- Octreotide controls carcinoid syndrome symptoms (diarrhea, flushing) in 60-70% of patients
- PROMID trial confirmed antiproliferative effect (HR 0.34 for tumor progression)
- Octreotide LAR depot formulation allows monthly dosing, improving compliance over thrice-daily subcutaneous injections
- Side effects are generally manageable: gallstone formation (15-30%), injection site reactions, GI disturbances, and transient hyperglycemia
- Escape phenomenon (tachyphylaxis) may occur in some patients over time, requiring dose adjustment or switch to alternative agents
Study Design
Narrative review of published literature on octreotide for NETs, covering pharmacology, clinical trial data, formulation development, and current guideline recommendations. Focused on both antisecretory and antiproliferative evidence.
Limitations
- Narrative review without systematic search methodology
- May not capture all relevant studies or provide quantitative synthesis
- Industry-funded review, which may influence presentation of evidence
Clinical Relevance
This review provides a practical clinical overview of octreotide in NET management, including the evolution from symptom control to established antiproliferative therapy. Useful reference for clinicians initiating patients on somatostatin analog therapy, covering formulation choices, dosing strategies, and management of common side effects.
Related
#research #narrative-review #octreotide #evidence-level-V